Please provide your email address to receive an email when new articles are posted on . Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily ...
Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...
If you have a certain kind of cancer or tumor, your doctor may prescribe Xgeva to help prevent serious bone problems. Xgeva is a prescription drug that’s used in adults to: Doctors may also prescribe ...
The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab). The proposed sBLA includes the addition ...
MADRID, Dec. 22, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ: ...
THOUSAND OAKS, Calif., June 13, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA ® (denosumab) for the ...
Sandoz has obtained the Food and Drug Administration’s clearance for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the only FDA-approved denosumab biosimilars, to treat all indications of ...
THOUSAND OAKS, Calif., Nov. 18, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Amgen's XGEVA(TM) (Denosumab) for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors --First Bone Targeted Therapy for Cancer Patients to Be ...
THOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating XGEVA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results